This book discusses the exciting potential for dermatology to embrace developments to enhance the profession’s valuable pattern recognition, diagnostic, and treatment skills. Personalized medicine (PM) and genomics are easily accessible and enable the customization of healthcare using molecular analysis to influence medical decisions, practices, and therapies for the individual patient. The evolution of the skin, and the manner in which dermatological conditions are described and managed, reveals the need to consider many aspects on a personal level. New research data are based on the use of evolutionary medicine and genomics to highlight how we can become more successful at finding the most efficacious types of antibiotic or therapy and dosage for a particular disease or pathogen and build a competitive edge by prevention and risk management against invasive viruses, bacteria, or wrongly administered drugs. As more is understood about what grows on us and how it all interacts, along with how the introduction of new antibiotics, biologics, and other therapies affect our skin’s ecological balance, this book aims to create a heightened sense of the importance and offerings of ecological dermatology.

Named a Best Book of 2020 by NPR and Vanity Fair One of Smithsonian's Ten Best Science Books of 2020 “A searching and vital explication of germ theory, social norms, and what the modern era is really doing to our bodies and our psyches.” —Vanity Fair A preventative medicine physician and staff writer for The Atlantic explains the surprising and unintended effects of our hygiene practices in this informative and entertaining introduction to the new science of skin microbes and probiotics. Keeping skin healthy is a booming industry, and yet it seems like almost no one agrees on what actually works. Confusing messages from health authorities and ineffective treatments have left many people desperate for reliable solutions. An enormous alternative industry is filling the void, selling products that are often of questionable safety and totally unknown effectiveness. In Clean, doctor and journalist James Hamblin explores how we got here, examining the science and culture of how we care for our skin today. He talks to dermatologists, microbiologists, allergists, immunologists, aestheticians, bar-soap enthusiasts, venture capitalists, Amish people, theologians, and straight-up scam artists, trying to figure out what it really means to be clean. He even experiments with giving up showers entirely, and discovers that he is not alone. Along the way, he realizes that most of our standards of cleanliness are less related to health than most people think. A major part of the picture has been missing: a little-known ecosystem known as the skin microbiome—the trillions of microbes that live on our skin and in our pores. These microbes are not dangerous; they’re more like an outer layer of skin that no one knew we had, and they influence everything from acne, eczema, and dry skin, to how we smell. The new goal of skin care will be to cultivate a healthy biome—and to embrace the meaning of “clean” in the natural sense. This can mean doing much less, saving time, money, energy, water, and plastic bottles in the process. Lucid, accessible, and deeply researched, Clean explores the ongoing, radical change in the way we think about our skin, introducing readers to the emerging science that will be at the forefront of health and wellness conversations in coming years.

This book is a quick reference guide to the new, more personalized approaches to the management of skin disorders that have emerged as a result of progress in our understanding of the genetic background and pathophysiology of skin diseases and the diversity of mechanisms underlying their clinical heterogeneity. A wide range of personalized and targeted therapies are described, including those for different skin cancers, chronic inflammatory skin diseases, and autoimmune diseases. In addition, readers will find that the book documents how research results in personalized medicine can be effectively transferred to dermatological practice and looks forward to future treatments that might be developed on the basis of recent research findings. The authors are all recognized experts in the field, and the text is presented in a reader-friendly format and well illustrated.

"Erika Engelhaupt, founding editor of National Geographic's Gory Details blog, explores oft-ignored but alluring facets of biology, anatomy, space exploration, nature, and more. Featuring reporting and interviews with leading researchers in the field, Gory Details illuminates the world's most intriguing real-world applications of science"--

Amid ongoing shifts world economic and political systems, the promise for future public health is more tenuous than ever. Will the today's economic systems sustain tomorrow's health? Will future generations inherit fair access to health and health care? The best hope for the health of future generations is the establishment of a well-grounded, global public health system for today. To that end, Global Public Health: Ecological Foundations addresses both the challenges and cooperative solutions of contemporary public health, all within a framework of social justice, environmental sustainability, and global cooperation. With an emphasis upon ecological foundations, this text approaches public health principles-history, foundations, topics, and applications-with a community-first perspective. By achieving global reach through cooperative, local interventions, this text illustrates that through the practice of public health we can also maintain the health of our world. Blending established wisdom with new perspectives, Global Public Health will stimulate better understanding of how the different streams of public health can work more synergistically to promote global health equity. It is a foundation on which future public health measures can be built and succeed.

Vector-borne infectious diseases, such as malaria, dengue fever, yellow fever, and plague, cause a significant fraction of the global infectious disease burden; indeed, nearly half of the world's population is infected with at least one type of vector-borne pathogen (CIESIN, 2007; WHO, 2004a). Vector-borne plant and animal diseases, including several newly recognized pathogens, reduce agricultural productivity and disrupt ecosystems throughout the world. These diseases profoundly restrict socioeconomic status and development in countries with the highest rates of infection, many of which are located in the tropics and subtropics. Although this workshop summary provides an account of the individual presentations, it also reflects an important aspect of the Forum philosophy. The workshop functions as a dialogue among representatives from different sectors and allows them to present their beliefs about which areas may merit further attention. These proceedings summarize only the statements of participants in the workshop and are not intended to be an exhaustive exploration of the subject matter or a representation of consensus evaluation. Vector-Borne Diseases : Understanding the Environmental, Human Health, and Ecological Connections, Workshop Summary (Forum on Microbial Threats) summarizes this workshop.

Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d’Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.